Monday, October 5, 2026

The bar is essentially undefined because CHRN has not disclosed a revenue or EBITDA baseline for the AI business; tonight's 'beat' is less important than whether management gives that baseline. The real story is whether the merged entity can show contracted demand and a credible funding path for AI compute capacity. A good quarter closes the merger cleanly and shows the stub is contained; a great one validates the ~$1.6B contribution assumption with multi-year contracted revenue or capacity commitments.

The bar looks supported by the order book: Q4 bookings were $60.7M, backlog $80.6M, effective backlog ~$100.6M, and FY27 guide $130-$150M. The real story is conversion and margin, not just whether the quarter beats, because FY26 revenue fell 15% to $50M and gross margin compressed to 38.5%. A good quarter likely shows backlog execution and guide maintenance; a great one could add a second Sonoma device or memory/HBM revenue path while stabilizing gross margin.

The bar likely hinges on whether PMT's Q4 ex-legacy healthcare +31.1% and FY2026 consolidated +9.4% growth are durable, with GES's open double-digit promise as the swing factor. A good quarter could show PMT momentum and stable 31.2% gross margin; a great one might pair that with GES double-digit growth, inventory visibility through 2030, and no NEE/GE-linked project-timing slippage. At 23.0x EV/EBITDA, the real story is whether margin and demand durability justify the re-rating.